Cancer (oncology) generics
Targeted therapies and biosimilars for lung, breast, ovarian, blood and other solid tumours — the largest cost burden for patients in Southeast Asia.
15 molecules. Open any card for the full monograph and price table.
Osimertinib High demand
Originator: Tagrisso · AstraZeneca
Adjuvant therapy after tumor resection in adults with NSCLC whose tumors have EGFR exon 19 delet
from BDT 333 (US$2.71 / 80 mg) · 13manufacturers
Cancer (oncology) →
Crizotinib High demand
Originator: Xalkori · Pfizer
Treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplast
from BDT 350 (US$2.85 / 250 mg) · 7manufacturers
Cancer (oncology) →
Alectinib
Originator: Alecensa · Roche (Genentech in the US; originated by Chugai Pharmaceutical)
Adjuvant treatment in adult patients following tumor resection of ALK-positive non-small cell lu
from BDT 500 (US$4.07 / 150 mg) · 1manufacturers
Cancer (oncology) →
Pralsetinib
Originator: Gavreto · Discovered by Blueprint Medicines; co-commercialised with Genentech (Roche) in the US and by Roche ex-US; Blueprint regained global rights (excluding Greater China) in 2023
Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detecte
Cancer (oncology) →
Capmatinib
Originator: Tabrecta · Novartis (discovered by Incyte, licensed to Novartis in 2009)
Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation
from BDT 1,500 (US$12.21 / 200 mg) · 1manufacturers
Cancer (oncology) →
Sotorasib
Originator: Lumakras · Amgen
As a single agent: adult patients with KRAS G12C-mutated locally advanced or metastatic non-smal
from BDT 1,000 (US$8.14 / 120 mg) · 2manufacturers
Cancer (oncology) →
Lorlatinib
Originator: Lorbrena · Pfizer Inc.
Metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kin
from BDT 1,660 (US$13.51 / 100 mg) · 2manufacturers
Cancer (oncology) →
Bevacizumab
Originator: Avastin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
Metastatic colorectal cancer (mCRC) in combination with intravenous fluorouracil-based chemother
Cancer (oncology) →
Trastuzumab
Originator: Herceptin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
Adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with
Cancer (oncology) →
Palbociclib High demand
Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)
In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal
from BDT 400 (US$3.26 / 125 mg) · 9manufacturers
Cancer (oncology) →
Abemaciclib
Originator: Verzenio · Eli Lilly and Company (Lilly USA, LLC)
In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant tre
from BDT 1,150 (US$9.36 / 200 mg) · 3manufacturers
Cancer (oncology) →
Olaparib High demand
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
Maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BR
from BDT 350 (US$2.85 / 150 mg) · 9manufacturers
Cancer (oncology) →
Niraparib
Originator: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)
Maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary per
from BDT 850 (US$6.92 / 100 mg) · 4manufacturers
Cancer (oncology) →
Ibrutinib High demand
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
Adult patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) - FDA
from BDT 320 (US$2.60 / 140 mg) · 8manufacturers
Cancer (oncology) →
Rituximab
Originator: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche
Non-Hodgkin's lymphoma (NHL): relapsed or refractory, low-grade or follicular, CD20-positive B-c
Cancer (oncology) →
Therapeutic areas
Medical and legal notice
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.